Avadel Shares Additional Data from Phase 3 Trial of Potential Narcolepsy Drug
“We are at a pivotal point in Avadel’s transformation, as we recently completed our pre-NDA meeting with the FDA and are currently focused on completing our NDA submission and filing for FT218.”
Read More